Wilco Kwanten

@FrancqueSven #AntwerpHepatology

🟣Management of obesity in advanced chronic liver disease 🔓#OpenAccess at 👉jhep-reports.eu/article/S2589-… #LiverX #LiverDisease #LiverHealth

📚🌍 How harmonised is gastroenterology training across Europe, and does it matter for workforce mobility and quality of care? This ESBGH Manpower survey of 33 countries reveals persistent heterogeneity in training structure, duration, certification and trainee output, despite two decades of calls for alignment. Only 12% of countries recognise the European Board examination as a national certification alternative, trainee numbers vary dramatically between nations, and 24% still impose post-training public service obligations. 🔎 The paper raises important questions about mobility, equity of specialist care, workforce planning, and whether Europe is any closer to a truly unified training framework. fg.bmj.com/content/early/… @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BritSocGastro @UEGWeek @ESGE_Endoscopy

Read our letter to the editor: Non-paired comparison of EUS-guided and transjugular liver approaches using different needles: can firm conclusions be made? tinyurl.com/mrerk8z2 #AntwerpHepatology @FrancqueSven

Interpreting liver blood test results can be challenging. How should clinicians interpret abnormal test results? New Education article offers guidance and a visual summary #BMJInfographic 🔗 bit.ly/4hYP9mF

Clinicians can enhance patient understanding by using numerical data instead of verbal probabilities, consistent denominators, absolute risk comparisons, and clear context for unfamiliar data types. ja.ma/4od48LR

Coming back from a wonderful symposium organised by dr Falk !

🤖 Potential dangers of AI in Medicine - De-Skilling - Mis-Skilling - Never-Skilling Nice editorial: thelancet.com/journals/lance…

@ArmandGirbes We behandelen in de eerste plaats mensen en niet enkel de ziekte of resultaten. Context en klachten zijn relevant (want je hoeft bijv. ook niet op elke afwijkende waarde springen). Bij mij altijd eerst een “babbel” en dan pas de rest … Mooie oproep!

Wie is de patiënt? Patiënten en hun familie konden mij altijd het diepst raken wanneer ze zeiden dat ze zich als een anoniem nummer behandeld voelden. Helaas kon ik dat vaak ook wel begrijpen, hoe erg het ook is. Hierbij mijn column voor artsen en verpleegkundigen.

Onderzoekers luiden alarmbel over georganiseerde fraude in de wetenschap: artikels en citaties te koop demorgen.be/tech-wetenscha…

Join the “Mind the Liver” study — because your story can help to change health care Are you living with MASLD (formerly NAFLD) or MASH (formerly NASH)? We invite you to take part in our international research study, "Mind the Liver," led by Dr Dana Ivancovsky Wajcman and Prof Jeffrey V. Lazarus at the Barcelona Institute for Global Health (ISGlobal). 🔍 By participating, you can help improve health care and support for yourself and others living with MASLD and MASH. MASLD is the most common liver disease in the world. It is often linked to obesity, type 2 diabetes, and heart disease and can also take a toll on your mental health, leading to stress, anxiety, or depression. MASLD can progress to MASH and lead to liver fibrosis, cirrhosis, and cancer. Mental health challenges may hinder engagement with MASLD and MASH treatment and care. Yet, mental health is rarely addressed in MASLD and MASH care. We want to change that, and we need your help. 🏥 What is involved in this? Take a 15–20-minute anonymous survey to help us understand: * Your experiences with mental health and liver care * Your lifestyle and medical history * Your barriers and facilitators to using mental health services ✅ Your participation is voluntary and confidential. You can select to not respond to any question or stop at any time. 🔹 You must be 18 or older and have a MASLD or MASH diagnosis to participate. 📅 Deadline to participate: June 30, 2025 ✉ Want your experience to make a difference? Click here [cunysph.az1.qualtrics.com/jfe/form/SV_0v… ] to get started: For more information, please contact: Dr. Dana Ivancovsky Wajcman — [danna.ivancovsky@isglobal.org](mailto:danna.ivancovsky@isglobal.org) #MindTheLiver #MASLD #MASH @ISGLOBALorg

In the (early) pathophysiology of MASLD the LSEC and microvascular alterations are key. Lanifibranor improves LSEC capillarisation and dysfunction! tinyurl.com/x37637j4 #AntwerpHepatology #AntwerpHypothesis @RautouE @FrancqueSven

🚨 Important Update 🚨 A new version of the EASL Guidelines App is now available! To access the latest features, please delete the old version and reinstall the app from your app store. 🆕 What’s new? ✅ 24 new calculators ✅ Access to EASL policy statements & policy dialogues ✅ Improved, user-friendly navigation and features Stay up to date with the latest in liver care—right at your fingertips. 📲 Download or update today! @AleksanderKrag @EASLedu

Who better than Christine Sempoux 👌to describe the 🔬pathology of vascular liver disease? Great digestive🔬🩺 session organised by Ann Driessen #antwerphepatology #belgiangastroenterologyweek 🇧🇪@esp @EASLnews @my_ueg @valerie_paradis @UKLiverPath @LiverPath_HPHS #LiverTwitter

🩺Sven Francque meets 🔬#BelgianGastroenterologyWeek 🇧🇪. Liver biopsy has reduced but significant role in #liver disease diagnosis depending on aetiology. Still ⭐️for #MASH! @EASLnews @ESP_Pathology @my_ueg @ukingreece @LiverPath_HPHS

Blue monday #Brabantsedag style! alles behalve triestig.

Joining a great event around organ transplantation including a discussion on donation after euthanasia. #foodforthought #donation #transplantation #UZA #AntwerpHepatology

📢 Join the ERN RARE-LIVER Webinar: Contraception & Fertility in Rare Liver Diseases 🗓️ 17 Dec 2024, 5 PM (CET) 💡 Topics: Best contraception options & pregnancy preparation for liver disease patients 👉 More info: bit.ly/3XYPcRk #Healthcare #RareDiseases #Fertility